

Publications Dr. De Laat

In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. (2013)

J Thromb Haemost. 2013 Jun;11(6):1111-8.
Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A.

Effect of laminar shear stress on the distribution of Weibel-Palade bodies in endothelial cells. (2012)

Thromb Res. 2012 Nov;130(5):741-5.
Dragt BS, van Agtmaal EL, de Laat B, Voorberg J.

Conformation of beta2glycoprotein I and its effect on coagulation. (2012)

Thromb Res. 2012 Oct;130 Suppl 1:S33-6.
Ninivaggi M, Kelchtermans H, Lindhout T, de Laat B.

Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. (2012)

Br J Haematol. 2012 Oct;159(1):94-103.
Du VX, van Os G, Kremer Hovinga JA, Dienava-Verdoold I, Wollersheim J, Ruggeri ZM, Fijnheer R, de Groot PG, de Laat B.

Thrombin generation: what have we learned? (2012)

Blood Rev. 2012 Sep;26(5):197-203.
Al Dieri R, de Laat B, Hemker HC.

Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. (2012)

Clin Chem. 2012 Aug;58(8):1252-9.
Ninivaggi M, Aritz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T.

Antibodies against domain I of beta2-glycoprotein I: the one and only? (2012)

Lupus. 2012 Jun;21(7):769-72.
Pelkmans L, de Laat B.

Elevated plasma von Willebrand factor and propeptide levels in Malawian children with malaria. (2011)

PLoS One. 2011;6(11):e25626.
Phiri HT, Bridges DJ, Glover SJ, van Mourik JA, de Laat B, M'baya B, Taylor TE, Seydel KB, Molyneux ME, Faragher EB, Craig AG, Bunn JE.

Increased active von Willebrand factor during disease development in the aging diabetic patient population. (2013)

Age (Dordr). 2013 Feb;35(1):171-7.
Chen SF, Xia ZL, Han JJ, Wang YT, Wang JY, Pan SD, Wu YP, Zhang B, Li GY, Du JW, Gao HQ, de Groot PG, de Laat B, Hollestelle MJ.

Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. (2011)

Arthritis Rheum. 2011 Dec;63(12):3960-8.
de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF, Maas C.

Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. (2011)

Am J Obstet Gynecol. 2011 Nov;205(5):485.e17-23.
Hunt BJ, Wu XX, de Laat B, Arslan AA, Stuart-Smith S, Rand JH.

Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. (2011)

J Thromb Haemost. 2011 Sep;9(9):1776-83.
Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J.

Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. (2011)

J Thromb Haemost. 2011 Aug;9(8):1657-9.
van Os GM, de Laat B, Kamphuisen PW, Meijers JC, de Groot PG.

Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in

haemophilia A. (2011)

J Thromb Haemost. 2011 Aug;9(8):1549-55.
Ninivaggi M, Dargaud Y, van Oerle R, de Laat B, Hemker HC, Lindhout T.

beta2-glycoprotein I: a novel component of innate immunity. (2011)

Blood. 2011 Jun 23;117(25):6939-47.
Agar C, de Groot PG, Mörgelin M, Monk SD, van Os G, Levels JH, de Laat B, Urbanus RT, Herwald H, van der Poll T, Meijers JC.

Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. (2011)

J Hypertens. 2011 May;29(5):922-7.
van den Born BJ, Löwenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, van Montfrans GA.

'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. (2011)

Lupus. 2011 Feb;20(2):191-205.
Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS.

Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. (2011)

J Thromb Haemost. 2011 Apr;9(4):738-47.
Dienava-Verdoold I, Boon-Spijker MG, de Groot PG, Brinkman HJ, Voorberg J, Mertens K, Derksen RH, de Laat B.

Autoantibodies directed against domain I of beta2-glycoprotein I. (2011)

Curr Rheumatol Rep. 2011 Feb;13(1):70-6.
de Laat B, de Groot PG.

An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. (2011)

J Thromb Haemost. 2011 Jan;9(1):149-53.
De Laat B, Derksen RH, Reber G, Musial J, Swadzba J, Bozic B, Cucnik S, Regnault V, Forastiero R, Woodhams BJ, De Groot PG.

Antiphospholipid antibodies and the protein C pathway. (2011)

Lupus. 2010 Apr;19(4):394-9.
Urbanus RT, de Laat B.

Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. (2010)

Blood. 2010 Feb 18;115(7):1472-4.
Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJ, Molyneux M, Combes V, O'Donnell JS, de Laat B, Craig A.

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. (2009)

Blood. 2009 Oct 22;114(17):3656-61.
de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, Doggen CJ.

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. (2009)

J Thromb Haemost. 2009 Nov;7(11):1767-73.
de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG.

A novel type 2A von Willebrand factor mutation (V1499E) associated with variable clinical expression. (2009)

J Pediatr Hematol Oncol. 2009 Apr;31(4):277-80.
van den Heuvel E, de Laat B, Eckmann CM, Michiels JJ, Schneppenheim R, Budde U, van Mourik JA, Versteegh FG.

Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. (2009)

PLoS Pathog. 2009 Mar;5(3):e1000349.
Larkin D, de Laat B, Jenkins PV, Bunn J, Craig AG, Terraube V, Preston RJ, Donkor C, Grau GE, van Mourik JA, O'Donnell JS.

Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of

resistance to activated protein C. (2008)

Blood Coagul Fibrinolysis. 2008 Dec;19(8):757-64.

de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA.

Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. (2008)

Semin Thromb Hemost. 2008 Jun;34(4):347-55.

de Groot PG, Derksen RH, de Laat B.

Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. (2008)

Nat Clin Pract Rheumatol. 2008 Apr;4(4):192-9.

de Laat B, Mertens K, de Groot PG.

Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRET-VWF73 assay. (2007)

J Thromb Haemost. 2007 Jun;5(6):1330-1.

Eckmann CM, De Laaf RT, Van Keulen JM, Van Mourik JA, De Laat B.

beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. (2007)

Blood. 2007 Sep 1;110(5):1483-91.

Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG.

Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. (2007)

Blood. 2007 Feb 15;109(4):1490-4.

de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH.

High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. (2006)

J Thromb Haemost. 2006 Jul;4(7):1619-21.

de Laat B, Derksen RH, de Groot PG.

Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. (2006)

Ann Rheum Dis. 2006 Nov;65(11):1468-72.

de Laat B, Derksen RH, Mackie IJ, Roest M, Schoormans S, Woodhams BJ, de Groot PG, van Heerde WL.

Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. (2006)

Blood. 2006 Mar 1;107(5):1916-24.

de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG.

IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. (2005)

Blood. 2005 Feb 15;105(4):1540-5.

de Laat B, Derksen RH, Urbanus RT, de Groot PG. [2\):327-41.](#)